XSHE
002198
Market cap266mUSD
Oct 09, Last price
3.55CNY
1D
1.14%
1Q
3.50%
Jan 2017
-73.66%
IPO
-1.57%
Name
Guangdong Jiaying Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Guangdong Jiaying Pharmaceutical Co., Ltd. is engaged in the comprehensive process of researching, developing, manufacturing, and marketing traditional Chinese medicines. Its operations span a vast international territory, encompassing Mainland China, Taiwan, Hong Kong, Macao, Southeast Asia, Europe, and the United States. The company primarily offers therapeutic solutions for a variety of health issues, such as throat conditions, common colds, orthopedic ailments, rheumatic diseases, gynecological disorders, conditions requiring heat-clearing, and gastrointestinal problems. These medical preparations are provided in numerous formats, including powders, tablets, capsules, granules, and pills. The distribution of its product line occurs through both independent agencies and direct sales points. The firm's operational hub is situated in Meizhou, China.
Key people
Junping Shi
Chief Financial Officer · since 2024
Yong Zeng
Finance Director · since 2025
Jun Sun
Secretary of the Board · since 2025
Bangjun Cao
Vice Chairman of the Board · since 2024
Neng Li
Chairman of the Board · since 2024
Yuan Yao
Director · since 2023
Yongping You
General Manager, Director · since 2024
Rurong Dai
Independent Director · since 2025
Independent Director · since 2021
Shanwei Li
Independent Director · since 2024
Junguo Li
Independent Director · since 2025
Chi Xu
Independent Director · since 2021
Headquarters & legal address
广东省梅州市东升工业园B区
梅州市, GD 510000
CN
梅州市, GD 510000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||